The main aim of this study is association of serum copper and vascular endothelial growth factor (VEGF-A) in postmenopausal bleeding (PMB) patients. Blood samples were collected from female patients suffering with postmenopausal bleeding (n = 50) as well as healthy females as controls (n = 50). Serum copper levels were estimated by spectrophotometric method and serum VEGF-A by ELISA technique and compared with ultr-
Introduction
Postmenopausal bleeding (PMB) is a common complaint in general gynecological practice. Women with PMB have around a 10 % chance of having endometrial carcinoma and therefore PMB always needs further evaluation [1] . Angiogenesis is the formation of new blood vessels from pre-existing vasculature and is a process fundamental to the human menstrual cycle. The uterine endometrium is a dynamic tissue that undergoes regular cycles of growth and breakdown, and has long been recognized as one of the few adult tissues where significant angiogenesis occurs on a routine, physiological basis. Abnormal angiogenesis may contribute to several different endometrial-related pathologies including endometrial cancer, endometriosis, menorrhagia and breakthrough bleeding [2] .
Copper is an essential trace element for all the living organisms and is an obligatory cofactor of angiogenesis [3] . It stimulates endothelial cell migration and proliferation and activates vascular growth factors. Hence the angiogenic activity of beta-fibroblastic growth factor (b-FGF), vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-a) and interleukin-1 (IL-1) were found to be copper dependent. Furthermore, copper repletion switches angiogenesis back ''on'' when a coppersufficient diet is restored, providing evidence for a novel, physiologic, and metabolic control pathway of angiogenesis [4] .
The VEGF family of proteins and their receptors play a crucial role as a potent stimulator of angiogenesis with many effects including endothelial cell proliferation, migration, and increase in vascular permeability and maintenance of vessel fragility [5] . VEGF correlates with physiological angiogenesis in the human endometrium and has a role in the development of the sub epithelial capillary plexus and functionalis microvessels during the proliferative phase of the menstrual cycle [6] . The VEGF family currently comprises of the following members-VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E. VEGF-A, previously known as vascular permeability factor (VPF) is important in luteal angiogenesis. Both estradiol and progesterone induce the expression of VEGF-A [7] . Tumor growth and spread of tumor cells requires angiogenesis. Incipient angiogenesis is not induced by tumor cell hypoxia but probably by proangiogenic factors. During growth, tumors depend on a further induction of vascular development for adequate oxygen and nutrient supply. If the oxygen supply is insufficient, the resulting hypoxia stimulates angiogenesis through up regulation of VEGF [3] . Previous studies have shown that the angiogenic activity of the growth factors (VEGF, b-FGF) were copper dependent and copper reduction resulted in the inhibition of their angiogenic activity [4] .
The hypothesis of the present study is that serum levels of copper and VEGF-A may be potential biomarkers of excessive angiogenesis in women with postmenopausal bleeding.
Materials and Methods

Patient Recruitment
This study was conducted at a rural hospital in south India. The patients as well as the control population were drawn from the same geographical area in order to ensure that the same environmental conditions and dietary habits were prevalent for both the groups. Here, the awareness of contraceptive measures for birth control is extremely poor. Fifty consecutive patients who had postmenopausal bleeding were recruited into the study. All patients agreed to participate in the study. The recruitment process consisted of taking a through history with a well designed proforma. History of environmental or occupational exposure to copper was taken as was the use of copper vessels for cooking and storing drinking water.
Patients were mostly in the proliferative phase of the menstrual cycle, as determined by the date of the last menstrual period and biopsy report. The women were between the ages of 50-72 years (mean age 58 years). Only patients who had irregular and excessive uterine bleeding continuously for more than 3 months were included in the study. Patients with prolonged bleeding in only one isolated month were not included as having dysfunctional uterine bleeding. They had no other associated gynecological diseases. All patients earlier had regular (27-30 days) menstrual cycles, lasting for 3-6 days and no history of dysmenorrhea during menstruation. All patients had proven fertility with no previous fertility problems and had delivered between one and six live infants with the last delivery being 1-3 years prior to the history of postmenopausal bleeding. They had not received any hormonal medication or used any copper containing intrauterine device for the past 1 year. None of these women were smokers. Other potential variables that could influence menstrual bleeding such as high body mass index (BMI), diabetes mellitus, hypertension and hypo-and hyperthyroidism was ruled out. Women who were pregnant or who had bleeding disorders were excluded from the study as were women with other diseases like fibroids, polyps and tumors. Height, weight and BMI were recorded.
The control population consisted 50 healthy age matched non-pregnant women who came for a dental check up to the hospital with a history of normal menstrual cycles. They had no history of any hormonal medication or use of any copper containing intrauterine device for the past 1 year. None of these women were smokers or had a history of diabetes mellitus, hypertension or thyroid disorders. The study was approved by the Institutional Review Board. The patient's consent for the study was obtained.
A random venous blood sample was collected for estimating serum copper and serum VEGF-A levels. Serum copper levels were estimated by using 3,5-di bromo pyridazole sulphanilic acid as coloring agent. Serum VEGF-A levels were estimated by sandwich ELISA technique. Quality controls were assessed in every series of samples to check the reproducibility and accuracy of the measurements.
Statistical Analysis
The statistical analysis was performed using SPSS software 11.0 version. Data was expressed as mean ± SD. Significance of difference between the patient and control groups observed is assessed by using the unpaired Student t test. p value \0.05 was considered to be significant.
Results
To see the effect of copper induced VEGF-A expression in postmenopausal bleeding, we have studied 50 PMB patients aged between 48 and 75 years (Group I) against 50 age matched non-pregnant healthy women with normal menstrual cycle (Group II). Among the demographic details of the patients and control when compared, especially serum copper, VEGF-A, and BMI levels were significantly increased (p \ 0.0001) in PMB patients ( Table 1 ). The majority of PMB patients (58 %) were between 48 and 75 years. The mean of parity among patient and control group was not significantly different between the two groups. The ultrasonographically measured endometrial thickness showed almost threefold increase thickness among the patient group (p \ 0.0001).
Serum copper, which is an obligatory cofactor of angiogenesis was measured in patients and controls. Serum copper levels were higher (162.92 ± 34.88 pg/ml,) in PMB patients than in controls (93.68 ± 8.32 pg/ml) ( Table 1) . It showed a twofold increase in patients when compared with controls and was highly significant (p \ 0.0001).
Copper and VEGF-A are sensitive indicators of PMB (Table 2) , the specificity increases when both the parameters are measured together with a high positive likelihood ratio. Analysis of the data produced the 2 9 2 table shown in Table 2 . Odds ratio for copper, VEGF-A and combination of copper and VEGF-A was 0.0426, 0.0947 and 0.0313 respectively, in all these cases odds ratio was \1. It indicates that copper induces the VEGF-A expression which inturn increases the angiogenesis in endometrium leads to PMB. Serum copper levels alone did not correlate with endometrial thickness.
A significant positive correlation between serum copper and serum VEGF-A levels was observed (r = 0.339, p \ 0.01). The present study also showed a significant negative correlation (r = -0.96) between serum VEGF-A and endometrial thickness (Table 3) . VEGF-A expression occur in the upper zone stroma of human endometrium. During menstruation only the deeper zones persist after the upper zones have sloughed away (11) . Additionally, after menstrual sloughing of the upper zones, VEGF-A and its receptors are coordinately expressed with intense expression of VEGF-A in the newly formed surface epithelium and significant increase in both VEGFR1 and VEGFR2 expression in multiple profiles of small vessels subjacent to the surface epithelium. In PMB patients Hb level are significantly decreased (10.08 ± 1.10, p \ 0.01) when compared to controls (10.84 ± 0.88). This may be due to excessive bleeding in PMB patients. In this present study comparitive study was done in patients with postmenopausal bleeding due to benign and malignant conditions by estimating VEGF and serum copper. Studies showed that significant increase in serum copper (p \ 0.0001) and a twofold increase in serum VEGF-A (p \ 0.0001) levels in patients with postmenopausal bleeding due to malignancy when compared with patients with bleeding due to benign conditions like cervicitis and fibroids (Table 4) .
Discussion
Angiogenesis is the formation of new blood vessels from pre-existing vasculature and is a process fundamental to the human menstrual cycle. The uterine endometrium is a dynamic tissue that undergoes regular cycles of growth and breakdown, where significant angiogenesis occurs on a routine, physiological basis. Abnormal angiogenesis may contribute to several different endometrial-related pathologies including endometrial cancer, endometriosis, menorrhagia and breakthrough bleeding [2] .
In a previous study [7] , the role of VEGF and copper was reported in dysfunctional uterine bleeding patients, whereas in this paper we are reporting our results in connection with the same parameters in PMB patients.
Copper is an obligatory cofactor of angiogenesis. It stimulates endothelial cell migration and proliferation and activates vascular growth factors. Hence the angiogenic activity of beta-fibroblastic growth factor (b-FGF), vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-a) and interleukin-1 (IL-1) were found to be copper dependent [5] .
Copper has been shown to influence the bioactivity or production of a number of angiogenic factors including VEGF-A [5, 8] and shares some of the pathways utilized by hypoxia to regulate VEGF-A expression [2, 5] demonstrated that copper is having anti-tumor activity [9] . Copper is also required in hemoglobin synthesis and in the catalysis of metabolic oxidation [10] . A specific amount of copper appears to be vital for angiogenesis to occur [11, 12] . Copper or copper complexes have been shown to directly stimulate angiogenesis in several animal model systems while copper chelation has been shown to inhibit angiogenesis [13] . Copper containing intra uterine devices (IUD) increases inflammatory action and uterine bleeding [14] .
Initial studies have been done on serum, secretory endometrium and menstrual blood copper levels in women using copper-T IUD. There was no change in the serum copper levels, but the secretory endometrium and menstrual blood copper levels were significantly increased in the endometrial tissue samples which were taken after insertion of IUD when compared with samples taken before insertion. With these results it was concluded that copper is not stored in basal layers of the endometrium but is continually released from the copper IUDs [15] . Thus previously serum copper levels were studied only in women using copper-T IUD.
Vaginal bleeding is the presenting sign in more than 90 % of postmenopausal patients with endometrial carcinoma. However, depending on age and risk factors, 1-14 % will have endometrial cancer [16, 17] . Tsikouras et al. [18] showed retrospective study, which included 275 patients with PMB, reported a 8.16 % prevalence of endometrial cancer in women with PMB and endometrial thickness \4 mm. Using a maximum 5-mm endometrial thickness, in a study of 182 women with PMB [19] . According to the results of Doorn et al. [20] study, 8 % of the women with recurrent bleeding turned out to have an endometrial carcinoma. These women had presented with a first episode of PMB.
In the present study serum copper and VEGF-A levels were studied in two groups of women, one with PMB and other with their respective age matched healthy controls.
In the present sudy comparitive study of patients with postmenopausal bleeding due to benign and malignant conditons by estimating VEGF and serum copper, showed that significant increase in serum copper and a twofold increase in serum VEGF-A levels in patients with postmenopausal bleeding due to malignancy when compared with patients with bleeding due to benign conditions like cervicitis and fibroids. This suggests that serum copper and VEGF-A levels are higher in malignancies when compared with benign lesions.
From a clinical perspective, in management of postmenopausal bleeding haematinics are usually given to treat anemia due to postmenopausal bleeding [21] . Most of these haematinics contain copper in them as copper helps to increase the absorption of iron [22] . This could lead to further elevation of copper levels which further stimulates VEGF-A leading to angiogenesis, resulting in postmenopausal bleeding or increased angiogenesis.
